Clinical Trial Update: A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating escalating doses of PRO131921 in relapsed or refractory chronic lymphocytic leukemia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• PRO131921

Snippet

Sponsor: Genentech, Inc. | Conditions: Chronic Lymphocytic Leukemia | Phase 1, Phase 2 | Status: TERMINATED